➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Express Scripts
Merck
Boehringer Ingelheim

Last Updated: July 23, 2021

DrugPatentWatch Database Preview

RALOXIFENE HYDROCHLORIDE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for raloxifene hydrochloride and what is the scope of freedom to operate?

Raloxifene hydrochloride is the generic ingredient in two branded drugs marketed by Lilly, Amneal Pharms, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for raloxifene hydrochloride. Six suppliers are listed for this compound.

Summary for RALOXIFENE HYDROCHLORIDE
Recent Clinical Trials for RALOXIFENE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Monash HealthPhase 4
Massachusetts General HospitalPhase 4
Laboratorios Grossman, S.A.Phase 3

See all RALOXIFENE HYDROCHLORIDE clinical trials

Pharmacology for RALOXIFENE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for RALOXIFENE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for RALOXIFENE HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
EVISTA TABLET;ORAL raloxifene hydrochloride 020815

US Patents and Regulatory Information for RALOXIFENE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sciegen Pharms Inc RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 206384-001 Oct 12, 2016 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Glenmark Pharms Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204491-001 Mar 22, 2016 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Cadila Pharms Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 211324-001 Aug 18, 2020 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RALOXIFENE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ⤷  Try it Free ⤷  Try it Free
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ⤷  Try it Free ⤷  Try it Free
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Express Scripts
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.